Microbion Corporation today announced that the company will be presenting a poster that highlights key clinical study design elements from an ongoing phase 2 study assessing safety and efficacy of topical pravibismane in subjects suffering from moderate infections associated with chronic diabetic foot ulcers at the 2023 Military Health System Research Symposium being held from August 14th to 17th, 2023, at the Gaylord Palms Resort and Convention Center in Kissimmee, FL. This Phase 2 study is fun
/PRNewswire/ - Microbion Corporation today announced that the company has been selected to present a poster highlighting the results from an E. coli CRISPR/Cas.
/PRNewswire/ - Microbion Corporation today announced that the company presented a poster focusing on pravibismane s activity against diabetic foot ulcer.